Cohort of Repeat Donor Experiences (CORE) Study
Public ClinicalTrials.gov record NCT07543965. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Plasma Protein Therapeutics Association (PPTA) sponsors the Cohort of Repeat Donor Experiences (CORE) Study. This is a prospective, observational cohort study that will follow Source Plasma donors for up to 2 years during the main study (launching in October 2026) ) and up to 3 months during the pilot inconducted April - September 2026. This study aims to confirm a lack of negative health effects Source Plasma donors may experience as a result of frequent plasmapheresis. The study will use data obtained through self-report surveys for the duration of the study along with periodic whole blood sample collections to test for CRP, ferritin, and IgG.
Study identification
- NCT ID
- NCT07543965
- Recruitment status
- Not yet recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 2,400 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 74 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2026 (Estimated)
- Primary completion
- Jul 1, 2028 (Estimated)
- Completion
- Apr 30, 2029 (Estimated)
- Last update posted
- Oct 19, 2026
2026 – 2029
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Takeda BioLife | Tempe | Arizona | 85284 | — |
| LFB Plasma | Pueblo | Colorado | 81008 | — |
| Kedplasma | Cocoa | Florida | 32922 | — |
| Takeda BioLife | Ammon | Idaho | 83406 | — |
| Grifols Biomat | Merrillville | Indiana | 46410 | — |
| Takeda BioLife | West Des Moines | Iowa | 50266 | — |
| Grifols Biomat | Wichita | Kansas | 67206 | — |
| Kedplasma | Bowling Green | Kentucky | 42101 | — |
| Takeda BioLife | Salisbury | Maryland | 21804 | — |
| Takeda BioLife | West Springfield | Massachusetts | 01089 | — |
| Kedplasma | El Paso | Texas | 79901 | — |
| Grifols Biomat | Humble | Texas | 77338 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07543965, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07543965 live on ClinicalTrials.gov.